Cargando…
Neoadjuvant Therapy in High-Risk Prostate Cancer
High-risk prostate cancer (PCa) is associated with higher rates of biochemical recurrence, clinical recurrence, metastasis, and PCa-specific death, compared to low-and intermediate-risk disease. Herein, we review the various definitions of high-risk PCa, describe the rationale for neoadjuvant therap...
Autores principales: | Ashrafi, Akbar N., Yip, Wesley, Aron, Monish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759181/ https://www.ncbi.nlm.nih.gov/pubmed/33376260 http://dx.doi.org/10.4103/iju.IJU_115_20 |
Ejemplares similares
-
Durable biochemical response following adrenal metastasectomy for oligometastatic castrate-resistant prostate cancer
por: Ashrafi, Akbar N., et al.
Publicado: (2020) -
Robotic surgery beyond the prostate
por: Aron, Monish
Publicado: (2014) -
Neoadjuvant chemotherapy for high‐risk prostatic adenocarcinoma
por: Brunner, Robert, et al.
Publicado: (2019) -
Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer
por: Sasaki, Takeshi, et al.
Publicado: (2021) -
Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis
por: Liu, Wen, et al.
Publicado: (2021)